Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ependymomas in the Posterior Fossa: An In-Depth Analysis of Molecular Classification, Treatment Protocols, and Clinical Outcomes (Part I on Ependymomas in Various Locations)

  • By

  • George W. Koutsouras

  • Francisco Rivera

  • Anthony M. Price

  • Derek S. Tsang

  • Adam Esbenshade

  • Vijay Ramaswamy

  • Peter B. Dirks

  • Michael C. Dewan

  • September 22, 2026

Share

  • 1

    Ependymal tumors account for about 5% of pediatric CNS tumors, with two-thirds originating in the posterior fossa.

  • 2

    Molecular profiling has shifted WHO classification of ependymomas from histologic to integrated molecular entities, including PFA and PFB.

  • 3

    PFA tumors are linked to poorer clinical outcomes due to epigenetic changes, while PFB tumors retain PRC2 regulation and show higher somatic aneuploidy.

  • 4

    MRI is essential for diagnosing posterior fossa ependymomas, revealing differences in imaging phenotypes between PFA and PFB tumors.

  • 5

    Surgical management aims for gross total resection, which significantly improves survival outcomes compared to subtotal resection.

Original Source(s)

Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments)

  • by George W. Koutsouras, Francisco Rivera, Anthony M. Price, Derek S. Tsang, Adam Esbenshade, Vijay Ramaswamy, Peter B. Dirks, Michael C. Dewan

  • September 22, 2026

Related Content

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
The evolution of RTOG and NRG Oncology CNS tumors clinical trials

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy